To investigate the association of mild renal impairment and coronary plaque in people living with HIV (PLHIV).
PLHIV and non-HIV controls with serum creatinine less than 1.5 mg/dl were investigated. Estimated glomerular filtration rate (eGFR) (calculated by CKD-EPI formula) was related to coronary plaque indices obtained by CT angiography.
One hundred and eighty-four PLHIV [HIV viral load, 49 (47,49) copies/ml, CD4+ cell count, median 536 (370, 770) cells/μl, duration HIV, 15 ± 7 years] and 72 HIV-negative controls without known cardiovascular disease (CVD) were studied. The two groups were well matched for traditional CVD risk factors. Serum creatinine (0.9 ± 0.2 vs. 0.9 ± 0.2 mg/dl, P = 0.96) and eGFR (96 ± 22 vs. 96 ± 24 ml/min per 1.73 m2, P = 0.99) were similar between PLHIV and non-HIV, respectively. In PLHIV, eGFR inversely related to total severity of coronary plaque score (r = −0.27, P = 0.002), total coronary segments with plaque (r = −0.21, P = 0.005), calcified plaque segments (r = −0.15, P = 0.045), and Agatston score (r = −0.21, P = 0.006). Adjusting for total Framingham point score, BMI, and HIV parameters, eGFR remained significantly associated with calcified plaque and Agatston score in PLHIV. In HIV negative controls, eGFR did not correlate with calcified plaque (r = −0.20, P = 0.10) or Agatston score (r = −0.13, P = 0.29). Among PLHIV, those with eGFR less than 90 ml/min per 1.73 m2 demonstrated increased total severity of coronary plaque score compared with those with eGFR greater than or equal to 90, P = 0.02). This relationship was stronger in PLHIV than the non-HIV group.
Our data highlight a robust relationship between subclinical renal impairment and coronary artery disease among PLHIV. Further research is needed to understand the relationship between mild renal impairment and CVD in HIV.
aProgram in Nutritional Metabolism
bCardiac MR PET CT Program, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Correspondence to Steven K. Grinspoon, MD, Massachusetts General Hospital, LON-207, 55 Fruit Street, Boston, MA 02114, USA. Tel: +1 617 726 3890; fax: +1 617 724 8998; e-mail: email@example.com
Received 25 July, 2018
Accepted 24 September, 2018
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (http://www.AIDSonline.com).